{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T06:37:16Z","timestamp":1723099036733},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T00:00:00Z","timestamp":1633564800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T00:00:00Z","timestamp":1633564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Chronic hepatitis C (CHC) is one of the most important comorbidities in patients with hereditary bleeding disorders (HBD). The present study aimed at evaluating the effectiveness of direct-acting antiviral agent (DAA)-based interferon-free HCV antiviral regimens in patients with HBD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and methods<\/jats:title><jats:p>The present study was performed on the patients with HBD and CHC between 2015 and 2019. Sofosbuvir-based interferon-free regimens with or without ribavirin were prescribed to treat HCV infection. The main endpoint of the study was to determine the sustained virologic response (SVR), assessed 12\u00a0weeks after the completion of treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 147 patients with a mean age of 41.1\u00a0years were enrolled in the study; 4.1% of them were co-infected with HIV, 25.2% had cirrhosis, and 76.9% of them were diagnosed with hemophilia A. HCV genotype-1 includes the largest number (68.1%) of patients. 46.3% of patients were treatment-na\u00efve and others had a treatment history with interferon-based regimens. Out of 147 patients, 15 patients were lost to follow-up during treatment or for SVR evaluation or discontinued treatment. 132 subjects completed treatment and were evaluated for SVR, 12\u00a0weeks after the completion of treatment. All of the patients achieved SVR 12 (SVR rate: 100%, 95% CI 97.2\u2013100%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Hepatitis C DAA-based regimens are the effective treatments for CHC in patients with HBD, regardless of the treatment modifiers such as previous treatment experience, cirrhosis, HIV co-infection, and HCV genotype.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12985-021-01659-0","type":"journal-article","created":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T19:21:07Z","timestamp":1633634467000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Treatment of hepatitis C virus infection with direct-acting antiviral agent-based regimens in Iranian patients with hereditary bleeding disorders"],"prefix":"10.1186","volume":"18","author":[{"given":"Heidar","family":"Sharafi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bita","family":"Behnava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alireza","family":"Azizi-saraji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Namvar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Anvar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shima","family":"Salimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyed Moayed","family":"Alavian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,7]]},"reference":[{"issue":"1","key":"1659_CR1","first-page":"35","volume":"31","author":"N Papadopoulos","year":"2018","unstructured":"Papadopoulos N, Argiana V, Deutsch M. Hepatitis C infection in patients with hereditary bleeding disorders: epidemiology, natural history, and management. Ann Gastroenterol. 2018;31(1):35.","journal-title":"Ann Gastroenterol"},{"issue":"4","key":"1659_CR2","doi-asserted-by":"publisher","first-page":"244","DOI":"10.5812\/hepatmon.6050","volume":"12","author":"SM Alavian","year":"2012","unstructured":"Alavian SM, Aalaei-Andabili SH. Lack of knowledge about hepatitis C infection rates among patients with inherited coagulation disorders in countries under the Eastern Mediterranean Region Office of WHO (EMRO): a meta-analysis. Hepat Mon. 2012;12(4):244.","journal-title":"Hepat Mon"},{"issue":"2","key":"1659_CR3","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/hae.13178","volume":"23","author":"C Walsh","year":"2017","unstructured":"Walsh C, Workowski K, Terrault N, Sax P, Cohen A, Bowlus C, et al. Ledipasvir\u2013sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disorders. Haemophilia. 2017;23(2):198\u2013206.","journal-title":"Haemophilia"},{"issue":"3","key":"1659_CR4","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1365-2516.2009.02188.x","volume":"16","author":"A Tagliaferri","year":"2010","unstructured":"Tagliaferri A, Rivolta G, Iorio A, Oliovecchio E, Mancuso M, Morfini M, et al. Mortality and causes of death in Italian persons with haemophilia, 1990\u20132007. Haemophilia. 2010;16(3):437\u201346.","journal-title":"Haemophilia"},{"issue":"4","key":"1659_CR5","doi-asserted-by":"publisher","first-page":"e22063","DOI":"10.1002\/jcla.22063","volume":"31","author":"M Keshvari","year":"2017","unstructured":"Keshvari M, Alavian SM, Behnava B, Pouryasin A, Craig JC, Sharafi H. Impact of IFNL 4 rs12979860 and rs8099917 polymorphisms on response to Peg-Interferon-\u03b1 and Ribavirin in patients with congenital bleeding disorder and chronic hepatitis C. J Clin Lab Anal. 2017;31(4):e22063.","journal-title":"J Clin Lab Anal"},{"issue":"6","key":"1659_CR6","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1093\/jac\/dkn119","volume":"61","author":"M Franchini","year":"2008","unstructured":"Franchini M, Mengoli C, Veneri D, Mazzi R, Lippi G, Cruciani M. Treatment of chronic hepatitis C in haemophilic patients with interferon and ribavirin: a meta-analysis. J Antimicrob Chemother. 2008;61(6):1191\u2013200.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"1659_CR7","doi-asserted-by":"publisher","first-page":"721","DOI":"10.5009\/gnl17209","volume":"11","author":"HW Lee","year":"2017","unstructured":"Lee HW, Yoo KY, Won JW, Kim HJ. Direct acting antiviral agents in Korean patients with chronic hepatitis C and hemophilia who are treatment-na\u00efve or treatment-experienced. Gut Liver. 2017;11(5):721.","journal-title":"Gut Liver"},{"issue":"3","key":"1659_CR8","doi-asserted-by":"publisher","first-page":"188","DOI":"10.2471\/BLT.19.231522","volume":"98","author":"H Perazzo","year":"2020","unstructured":"Perazzo H, Castro R, Luz PM, Banholi M, Goldenzon RV, Cardoso SW, et al. Effectiveness of generic direct-acting agents for the treatment of hepatitis C: systematic review and meta-analysis. Bull World Health Organ. 2020;98(3):188.","journal-title":"Bull World Health Organ"},{"key":"1659_CR9","unstructured":"World Health Organization. Global health sector strategy on viral hepatitis 2016\u20132021 2016. Available from: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/246177\/WHO-HIV-2016.06-eng.pdf?sequence=1."},{"issue":"8","key":"1659_CR10","doi-asserted-by":"publisher","first-page":"e40959","DOI":"10.5812\/hepatmon.guideline","volume":"16","author":"SM Alavian","year":"2016","unstructured":"Alavian SM, Hajarizadeh B, Lankarani KB, Sharafi H, Daryani NE, Merat S, et al. Recommendations for the clinical management of hepatitis C in Iran: a consensus-based national guideline. Hepat Mon. 2016;16(8):e40959.","journal-title":"Hepat Mon"},{"issue":"5","key":"1659_CR11","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1080\/10245332.2015.1125080","volume":"21","author":"A Dorgalaleh","year":"2016","unstructured":"Dorgalaleh A, Dadashizadeh G, Bamedi T. Hemophilia in Iran. Hematology. 2016;21(5):300\u201310.","journal-title":"Hematology"},{"issue":"1","key":"1659_CR12","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1016\/j.jhep.2014.07.027","volume":"61","author":"E Gower","year":"2014","unstructured":"Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61(1):S45\u201357.","journal-title":"J Hepatol"},{"issue":"11","key":"1659_CR13","doi-asserted-by":"publisher","first-page":"4","DOI":"10.5812\/hepatmon.63956","volume":"17","author":"SM Alavian","year":"2017","unstructured":"Alavian SM, Sharafi H. Update on recommendations for the clinical management of hepatitis C in Iran 2017. Hepat Mon. 2017;17(11):4.","journal-title":"Hepat Mon"},{"issue":"1","key":"1659_CR14","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jhep.2015.03.025","volume":"63","author":"European Association for the Study of the Liver 2017","year":"2015","unstructured":"European Association for the Study of the Liver 2017. EASL recommendations on treatment of hepatitis C 2015. J Hepatol. 2015;63(1):199\u2013236.","journal-title":"J Hepatol"},{"issue":"1","key":"1659_CR15","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jhep.2016.09.001","volume":"66","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016. J Hepatol. 2017;66(1):153\u201394.","journal-title":"J Hepatol"},{"issue":"2","key":"1659_CR16","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","volume":"69","author":"European Association for the Study of the Liver","year":"2018","unstructured":"European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69(2):461\u2013511.","journal-title":"J Hepatol"},{"issue":"5","key":"1659_CR17","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1111\/liv.14337","volume":"40","author":"ME Mancuso","year":"2020","unstructured":"Mancuso ME, Linari S, Santagostino E, Bartolozzi D, D\u2019Ambrosio R, Borghi M, et al. High rate of sustained virological response with direct-acting antivirals in haemophiliacs with HCV infection: a multicenter study. Liver Int. 2020;40(5):1062\u20138.","journal-title":"Liver Int"},{"key":"1659_CR18","first-page":"72","volume":"21","author":"M Keshvari","year":"2016","unstructured":"Keshvari M, Alavian SM, Behnava B, Pouryasin A, Sharafi H. The interferon lambda 4 rs368234815 predicts treatment response to pegylated-interferon alpha and ribavirin in hemophilic patients with chronic hepatitis C. J Res Med Sci Off J Isfahan Univ Med Sci. 2016;21:72.","journal-title":"J Res Med Sci Off J Isfahan Univ Med Sci"},{"issue":"4","key":"1659_CR19","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.jhep.2017.06.033","volume":"67","author":"JV Lazarus","year":"2017","unstructured":"Lazarus JV, Wiktor S, Colombo M, Thursz M. Micro-elimination\u2013A path to global elimination of hepatitis C. J Hepatol. 2017;67(4):665\u20136.","journal-title":"J Hepatol"},{"issue":"10","key":"1659_CR20","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1093\/cid\/ciy585","volume":"67","author":"C Hepatitis","year":"2018","unstructured":"Hepatitis C. guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis. 2018;67(10):1477\u201392.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"1659_CR21","doi-asserted-by":"publisher","first-page":"70214795","DOI":"10.1371\/journal.pone.0214795","volume":"14","author":"P Buggisch","year":"2019","unstructured":"Buggisch P, Wursthorn K, Stoehr A, Atanasov PK, Supiot R, Lee J, et al. Real-world effectiveness and safety of sofosbuvir\/velpatasvir and ledipasvir\/sofosbuvir hepatitis C treatment in a single centre in Germany. PLoS ONE. 2019;14(4):70214795.","journal-title":"PLoS ONE"},{"issue":"3","key":"1659_CR22","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jhep.2018.11.011","volume":"70","author":"R D'Ambrosio","year":"2019","unstructured":"D\u2019Ambrosio R, Pasulo L, Puoti M, Vinci M, Schiavini M, Lazzaroni S, et al. Real-world effectiveness and safety of glecaprevir\/pibrentasvir in 723 patients with chronic hepatitis C. J Hepatol. 2019;70(3):379\u201387.","journal-title":"J Hepatol"},{"issue":"1","key":"1659_CR23","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1053\/j.gastro.2016.09.045","volume":"152","author":"P Kwo","year":"2017","unstructured":"Kwo P, Gane EJ, Peng C-Y, Pearlman B, Vierling JM, Serfaty L, et al. Effectiveness of elbasvir and grazoprevir combination, with or without ribavirin, for treatment-experienced patients with chronic hepatitis C infection. Gastroenterology. 2017;152(1):164\u201375.","journal-title":"Gastroenterology"},{"issue":"2","key":"1659_CR24","doi-asserted-by":"publisher","first-page":"188","DOI":"10.5604\/16652681.1231577","volume":"16","author":"MS Rezaee-Zavareh","year":"2017","unstructured":"Rezaee-Zavareh MS, Hesamizadeh K, Behnava B, Alavian SM, Gholami-Fesharaki M, Sharafi H. Combination of ledipasvir and sofosbuvir for treatment of hepatitis C virus genotype 1 infection: systematic review and meta-analysis. Ann Hepatol. 2017;16(2):188\u201397.","journal-title":"Ann Hepatol"},{"issue":"6","key":"1659_CR25","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.jhep.2017.01.025","volume":"66","author":"Q-L Zeng","year":"2017","unstructured":"Zeng Q-L, Xu G-H, Zhang J-Y, Li W, Zhang D-W, Li Z-Q, et al. Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: a real-life observational study. J Hepatol. 2017;66(6):1123\u20139.","journal-title":"J Hepatol"},{"issue":"1","key":"1659_CR26","first-page":"1","volume":"17","author":"S Merat","year":"2017","unstructured":"Merat S, Sharifi AH, Haj-Sheykholeslami A, Poustchi H, Fattahi B, Nateghi-Baygi A, et al. The efficacy of 12 weeks of sofosbuvir, daclatasvir, and ribavirin in treating hepatitis C patients with cirrhosis, genotypes 1 and 3. Hepat Mon. 2017;17(1):1.","journal-title":"Hepat Mon"},{"key":"1659_CR27","doi-asserted-by":"publisher","DOI":"10.5812\/hepatmon.12216","author":"H Sharafi","year":"2017","unstructured":"Sharafi H, Nikbin M, Alavian SH, Behnava B, Alavian SM. Efficacy and Safety of generic sofosbuvir\/ledipasvir fixed-dose combination in Iranian patients with chronic hepatitis C virus infection. Hepat Mon. 2017. https:\/\/doi.org\/10.5812\/hepatmon.12216.","journal-title":"Hepat Mon"},{"issue":"1","key":"1659_CR28","first-page":"41","volume":"11","author":"H Sharafi","year":"2020","unstructured":"Sharafi H, Alavian SH, Behnava B, Rezaee-Zavareh MS, Nikbin M, Alavian SM. Real-life efficacy of generic sofosbuvir\/ledipasvir for treatment of Iranian patients with chronic hepatitis C: a cohort study. Casp J Intern Med. 2020;11(1):41.","journal-title":"Casp J Intern Med"},{"issue":"6","key":"1659_CR29","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1111\/hae.13829","volume":"25","author":"L Fransen","year":"2019","unstructured":"Fransen L, D\u2019hondt P, Bielen R, Van den Ende N, Robaeys G, Peerlinck K, et al. Elimination of hepatitis C virus infection in patients with haemophilia in Belgium: a single-centre experience. Haemophilia. 2019;25(6):1028\u201334.","journal-title":"Haemophilia"},{"key":"1659_CR30","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1111\/liv.14413","volume":"40","author":"TP Guedes","year":"2020","unstructured":"Guedes TP, Garrido M, Morais S, Pedroto I. High rate of SVR with DAA in haemophiliacs with HCV infection: three decades of follow-up of a Portuguese single-centre cohort. Liver Intl: Off J Int Assoc Study Liver. 2020;40:1783\u20134.","journal-title":"Liver Intl: Off J Int Assoc Study Liver"},{"issue":"4","key":"1659_CR31","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1097\/QAI.0000000000001271","volume":"74","author":"A Nagao","year":"2017","unstructured":"Nagao A, Hanabusa H. Brief report: the impact of ledipasvir\/sofosbuvir on HIV-positive and HIV-negative Japanese hemophilia patients with 1, 4, and mixed-genotype HCV. JAIDS J Acquir Immune Defic Syndr. 2017;74(4):418\u201322.","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"issue":"2","key":"1659_CR32","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/hae.12791","volume":"22","author":"C Stedman","year":"2016","unstructured":"Stedman C, Hyland R, Ding X, Pang P, McHutchison J, Gane E. Once daily ledipasvir\/sofosbuvir fixed-dose combination with ribavirin in patients with inherited bleeding disorders and hepatitis C genotype 1 infection. Haemophilia. 2016;22(2):214\u20137.","journal-title":"Haemophilia"},{"issue":"10","key":"1659_CR33","doi-asserted-by":"publisher","first-page":"e0186255","DOI":"10.1371\/journal.pone.0186255","volume":"12","author":"H Uemura","year":"2017","unstructured":"Uemura H, Tsukada K, Mizushima D, Aoki T, Watanabe K, Kinai E, et al. Interferon-free therapy with direct acting antivirals for HCV\/HIV-1 co-infected Japanese patients with inherited bleeding disorders. PLoS ONE. 2017;12(10):e0186255.","journal-title":"PLoS ONE"},{"issue":"30","key":"1659_CR34","doi-asserted-by":"publisher","first-page":"e16524","DOI":"10.1097\/MD.0000000000016524","volume":"98","author":"H Xiao","year":"2019","unstructured":"Xiao H, Chen J, Wang J, Li J, Yang F, Lu H. Antiviral therapy for HCV in hemophilia A patients with HIV-1 co-infection. Medicine. 2019;98(30):e16524.","journal-title":"Medicine"},{"issue":"11","key":"1659_CR35","first-page":"1611","volume":"36","author":"KV Kowdley","year":"2016","unstructured":"Kowdley KV, Nelson DR, Lalezari JP, Box T, Gitlin N, Poleynard G, et al. On-treatment HCV RNA as a predictor of sustained virological response in HCV genotype 3-infected patients treated with daclatasvir and sofosbuvir. Liver Int Off J Int Assoc Study Liver. 2016;36(11):1611\u20138.","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"issue":"8","key":"1659_CR36","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1111\/liv.14486","volume":"40","author":"H Karimi-Sari","year":"2020","unstructured":"Karimi-Sari H, Rezaee-Zavareh MS. COVID-19 and viral hepatitis elimination programs: Are we stepping backward? Liver Int. 2020;40(8):2042.","journal-title":"Liver Int"},{"issue":"4","key":"1659_CR37","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s12072-020-10054-w","volume":"14","author":"C Gregory","year":"2020","unstructured":"Gregory C, Rino G, Richard G, Ghazinyan H, Dokmeci K, Tatsuo K, et al. Clinical practice guidance for hepatology and liver transplant providers during the COVID-19 pandemic: APASL expert panel consensus recommendations. Hepatol Int. 2020;14(4):415\u201328.","journal-title":"Hepatol Int"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-021-01659-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-021-01659-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-021-01659-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T13:12:24Z","timestamp":1699621944000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-021-01659-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,7]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1659"],"URL":"https:\/\/doi.org\/10.1186\/s12985-021-01659-0","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,7]]},"assertion":[{"value":"15 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was reviewed and approved by the Ethics Committee of Baqiyatallah University of Medical Sciences (ethical code: IR.BMSU.REC.1398.145). Besides, due to the retrospective nature of the study, informed consent was inapplicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors stated that they had no interests which might be perceived as posing a conflict or bias.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"199"}}